Dominik Paul Modest
YOU?
Author Swipe
View article: Supplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Overview of antibodies used for staining and cutoffs in TMA analysis.
View article: Supplementary Table S10 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S10 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Multivariate Cox regression analyses with regard to prognostic impact of Immunoactivation-Score in terms of progression-free survival and overall survival since start of maintenance treatment.
View article: Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Analysis of progression-free survival within the maintenance therapy set by high/low immune expression and treatment arm. Mean Values of Epithelial Tumor and Stromal Cells.
View article: Supplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Risk analysis of Overall Response Rates in the epithelial tumor of tumor center and invasive margin in the Maintenance set by treatment arm.
View article: Supplementary Figure S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Forest plot of univariate Cox Regression Analysis of progression-free survival and overall survival within epithelial tumor expression in the invasive margin and overall stromal expression of the induction therapy set.
View article: Supplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Odds Ratios and 95% Confidence Intervals regarding ORR of immunoexpression in the epithelial tumor in the tumor center and the invasive margin after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
View article: Data from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Data from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Purpose:Tumor immune cell infiltration patterns in the tumor microenvironment serve as prognostic biomarkers in metastatic colorectal cancer. This study analyzed the spatially resolved tumor immune microenvironment for prognostic and predi…
View article: Supplementary Table S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Odds Ratios and 95% Confidence Intervals regarding ORR of immunoexpression in the epithelial tumor in the tumor center and the invasive margin after exclusion of cases with BRAF V600E and MSI – Induction Set
View article: Supplementary Table S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Representativeness of study participants
View article: Supplementary Table S9 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S9 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Interaction of positive/negative Immunoscore and Immunoactivation Score with maintenance treatment in terms of PFS and OS in the PanaMa trial.
View article: Supplementary Table S13 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S13 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Hazard Ratios and 95% Confidence Intervals regarding OS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
View article: Supplementary Table S7 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S7 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Hazard Ratios and 95% Confidence Intervals regarding OS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Induction Set.
View article: Supplementary Table S12 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S12 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Hazard Ratios and 95% Confidence Intervals regarding PFS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
View article: Supplementary Table S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Confidence intervals, medians and P of IHC measurements. Paired-sampled t-test of stromal and epithelial immune infiltration in each tumor region.
View article: Supplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Analysis of overall survival within the maintenance therapy set by high/low immune expression, tumor region and treatment arm.
View article: Supplementary Figure S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Risk analysis of Overall Response Rates in the Induction set.
View article: Supplementary Table S8 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S8 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Patient Characteristics of induction and maintenance PanaMa populations and positive/negative Immunoactivation Score subpopulations.
View article: Supplementary Table S6 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S6 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Hazard Ratios and 95% Confidence Intervals regarding PFS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Induction Set.
View article: The Prognostic Role of Frailty and Its Recognition With Simple FRAIL and Fried Frailty Questionnaires in Advanced Cancer Patients
The Prognostic Role of Frailty and Its Recognition With Simple FRAIL and Fried Frailty Questionnaires in Advanced Cancer Patients Open
Background Patients with advanced cancer frequently suffer from frailty associated with vulnerability and adverse outcomes. Our aim was to assess the prevalence of frailty and elucidate the utility of two commonly used frailty questionnair…
View article: Supplementary Table S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Patient Characteristics of PanaMa population and TMA-subpopulation.
View article: Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials Open
PURPOSE Human epidermal growth factor receptor 2 (HER2) amplification/overexpression (HER2-pos) is detected in 5% of RAS/BRAF wild-type metastatic colorectal cancers (mCRCs). Its prognostic/predictive role in terms of benefit from anti-EGF…
View article: Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials Open
Tumor sidedness and hyperselection status significantly influence maintenance strategy efficacy in mCRC. For left-sided, negative hyperselected patients, Panitumumab monotherapy may optimize efficacy while minimizing toxicity. Further inve…
View article: Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the <scp>EMPATICC</scp> trial
Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the <span>EMPATICC</span> trial Open
Aims End‐stage cancer may resemble a heart failure (HF)‐like phenotype marked by cardiac wasting, dysfunction, and symptoms such as dyspnoea, congestion, and impaired physical function. The EMPATICC (EMPower the heArt of patients with Term…
View article: Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial)
Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial) Open
Background and Aims Advanced cancer may resemble a heart failure (HF)-like phenotype marked by cardiac wasting, dyspnoea, congestion, and/or physical dysfunction. The trial evaluated safety and efficacy of HF therapy among patients with ad…
View article: Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO
Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO Open
The distribution of PD events does not follow a Gaussian pattern, with the highest density observed between the third and fourth reassessment of a bimonthly surveillance schedule. In clearly unresectable patients, restaging should focus on…
View article: Optimized heart failure therapy in patients with very advanced cancer in palliative care: dosing strategies from the EMPATICC trial
Optimized heart failure therapy in patients with very advanced cancer in palliative care: dosing strategies from the EMPATICC trial Open
Cardiac wasting occurs in patients with end-stage cancer, leading to the development of heart failure (HF)-like symptoms characterized by dyspnea, reduced physical function, and diminished quality of life. The EMPATICC (EMPower the heArt o…
View article: Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer
Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer Open
Aims Cardiac wasting‐associated cardiomyopathy in patients with advanced cancer is characterized by loss of left ventricular (LV) mass and independently associated with poor prognosis. Better understanding of this very prevalent cardiomyop…
View article: FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA phase II randomized trial
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA phase II randomized trial Open
Randomized, non-comparative, open-label, multi-center phase II study to evaluate mFOLFOX (D1=D15: oxaliplatin 85 mg/m2, folinic acid: 400 mg/m2, 5FU bolus: 400 mg/m2 followed by 5FU: 2400 mg/m2 IV infusion over 46 h) and mFOLFIRINOX (mFOLF…
View article: Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial
Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial Open
The survival benefit of treatment with FTD/TPI + bevacizumab versus FTD/TPI is likely associated with the improvement of ETS and DpR.
View article: 39P AntiEGFR-based maintenance versus stop&go strategy in patients with left-sided, non MSI, RAS/BRAF wild type (wt) metastatic colorectal cancer (mCRC): Individual patient data (IPD) pooled analysis of randomized clinical trials (RCTs)
39P AntiEGFR-based maintenance versus stop&go strategy in patients with left-sided, non MSI, RAS/BRAF wild type (wt) metastatic colorectal cancer (mCRC): Individual patient data (IPD) pooled analysis of randomized clinical trials (RCTs) Open